D
DMC Biotechnologies
DMC Biotechnologies is the low cost sustainable transformation of multiple product markets
About DMC Biotechnologies
DMC Biotechnologies operates in the biomanufacturing sector, focusing on the sustainable and cost-effective production of bio-based chemicals. The company leverages its innovative technology and metabolic engineering expertise to rapidly commercialize a broad range of bio-based chemicals through precision fermentation. This process allows for the local production of materials using agricultural feedstocks, enabling customers to diversify their supply chains and increase resilience against global disruptions. DMC's business model revolves around collaborating with various industries to provide a reliable and economically sound supply of essential chemicals. The company generates revenue by offering its biomanufacturing services and products to clients in diverse markets, including agriculture, pharmaceuticals, and consumer goods. With a promising pipeline of products under development, DMC aims to revolutionize the chemical production industry by making it more sustainable and efficient.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Morrisville, United States
- Employees
- 41
- Open positions
- 2
- Dealroom signal
- 59.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Commerce, Chemical, Synthetic Biology, Spinout, Biotech and Pharma, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2021 | $34M | $136M | Capricorn Partners · Michelin · SCG · Breakthrough Energy Ventures | ↗ |
| SERIES A✓Equity / VC | Dec 2019 | $1M | $4M | Capricorn Partners · Boulder Ventures · Breakthrough Energy Ventures · Sofinnova Partners | — |
Growth signals
Latest recorded traffic for DMC Biotechnologies is 3.7K monthly website visits, up 37% over the last three months. DMC Biotechnologies's team declined 19.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US National Science Foundation
Capricorn Partners
Series A6 investors entered at this stage
Boulder Ventures
Breakthrough Energy Ventures
Sofinnova Partners
Cibus Capital
Michelin- SCSCG
Other known investors4 additional known investors
Duke University
Quest for Growth
Small Business Innovation Research
Syensqo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DMC Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DMC Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.